Wednesday, October 18, 2017 8:47:53 AM
BLRX - 1.09 Pre-market now at 1.13/1.15
BioLineRx Initiates Phase 1/2 Study of BL-8040 with Atezolizumab to Treat Gastric Cancer; Shares Up 1% Early
BioLineRx Initiates Phase 1/2 Study of BL-8040 with Atezolizumab to Treat Gastric Cancer; Shares Up 1% Early
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
